Mirati Therapeutics, San Diego, California 92130, United States.
ZoBio BV, J.H. Oortweg 19, Leiden 2333 CH, Netherlands.
J Med Chem. 2024 Jan 11;67(1):774-781. doi: 10.1021/acs.jmedchem.3c02140. Epub 2023 Dec 29.
SOS1 and SOS2 are guanine nucleotide exchange factors that mediate RTK-stimulated RAS activation. Selective SOS1:KRAS PPI inhibitors are currently under clinical investigation, whereas there are no reports to date of SOS2:KRAS PPI inhibitors. SOS2 activity is implicated in MAPK rebound when divergent SOS1 mutant cell lines are treated with the SOS1 inhibitor BI-3406; therefore, SOS2:KRAS inhibitors are of therapeutic interest. In this report, we detail a fragment-based screening strategy to identify X-ray cocrystal structures of five diverse fragment hits bound to SOS2.
SOS1 和 SOS2 是鸟嘌呤核苷酸交换因子,可介导 RTK 刺激的 RAS 激活。目前正在临床研究中选择性 SOS1:KRAS PPI 抑制剂,而迄今为止尚无 SOS2:KRAS PPI 抑制剂的报道。当用 SOS1 抑制剂 BI-3406 处理不同 SOS1 突变细胞系时,SOS2 活性与 MAPK 反弹有关;因此,SOS2:KRAS 抑制剂具有治疗意义。在本报告中,我们详细介绍了一种基于片段的筛选策略,以确定与 SOS2 结合的五个不同片段的 X 射线共晶结构。